LPLena Pfitzer

Lena Pfitzer

*This is an algorithmically generated author record based on publicly available information.

Lena Pfitzer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification

    by Lena Pfitzer, Gitta Boons, Lien Lybaert, Wim van Criekinge, Cedric Bogaert, Bruno Fant

    Background: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-positive rates and limiting the clinical utility of antigen selection methods. Methods: We developed the neoIM (for “neoantigen immunogenicity”) model, a first-in-class, high-precision immunogenicity prediction tool that overcomes these limitations by focusing exclusively on overall CD8 T-cell response rather than MHC binding. neoIM, a random forest classifier, was trained solely on MHC-presented non-self peptides (n = 61.829). Its performance was assessed against that of currently existing alternatives on several in vitro immunogenicity datasets. In addition, its clinical impact was investigated in two retrospective analyses of clinical trial data by assessing the effect of neoIM-based antigen selection on the positive immunogenicity rate of personal vaccine designs. Finally, the potential for neoIM as a biomarker was investigated by assessing the correlation between neoIM scores and overall survival in a melanoma patient cohort treated with checkpoint inhibitors (CPI). Results: neoIM was found to substantially outperform publicly available tools in regards to in vitro benchmarks based on ELISpot assays, with an increase in predictive power of at least 30%, reducing false positives and improving target selection efficiency. In addition, using neoIM scores during patient-specific antigen prioritization and selection was shown to yield up to 50% more clinically actionable antigens for individual patients in two recent clinical trials. Finally, we showed that neoIM could further refine response prediction to checkpoint inhibition therapy, further demonstrating the importance of evaluating neoantigen immunogenicity. Conclusions: These findings establish neoIM as the first computational tool capable of accurately predicting epitope immunogenicity beyond MHC affinity. By enabling more precise target discovery and prioritization, neoIM has the potential to accelerate the development of next-generation antigen-based immunotherapies.


  • Open Access

    Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model

    by Lena Pfitzer, Lien Lybaert, Cedric Bogaert, Bruno Fant

    The identification of immunogenic peptides that will elicit a CD8+ T cell-specific immune response is a critical step for various immunotherapeutic strategies such as cancer vaccines. Significant research effort has been directed towards predicting whether a peptide is presented on class I major histocompatibility complex (MHC I) molecules. However, only a small fraction of the peptides predicted to bind to MHC I turn out to be immunogenic. Prediction of immunogenicity, i.e. the likelihood for CD8+ T cells to recognize and react to a peptide presented on MHC I, is of high interest to reduce validation costs, de-risk clinical studies and increase therapeutic efficacy especially in a personalized setting where in vitro immunogenicity pre-screening is not possible. To address this, we present neoIM, a random forest classifier specifically trained to classify short peptides as immunogenic or non-immunogenic. This first-in-class algorithm was trained using a positive dataset of more than 8000 non-self immunogenic peptide sequences, and a negative dataset consisting of MHC I-presented peptides with one or two mismatches to the human proteome for a closer resemblance to a background of mutated but non-immunogenic peptides. Peptide features were constructed by performing principal component analysis on amino acid physicochemical properties and stringing together the values of the ten main principal components for each amino acid in the peptide, combined with a set of peptide-wide properties. The neoIM algorithm outperforms the currently publicly available methods and is able to predict peptide immunogenicity with high accuracy (AUC=0.88). neoIM is MHC-allele agnostic, and in vitro validation through ELISPOT experiments on 33 cancer-derived neoantigens have confirmed its predictive power, showing that 71% of all immunogenic peptides are contained within the top 30% of neoIM predictions and all immunogenic peptides were included when selecting the top 55% of peptides with the highest neoIM score. Finally, neoIM results can help to better predict the response to checkpoint inhibition therapy, especially in low TMB tumors, by focusing on the number of immunogenic variants in a tumor. Overall, neoIM enables significantly improved identification of immunogenic peptides allowing the development of more potent vaccines and providing new insights into the characteristics of immunogenic peptides.